Status:
COMPLETED
A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Participants With Epilepsy Aged 12 Years or Older
Lead Sponsor:
Eisai Pharmaceuticals India Pvt. Ltd
Conditions:
Partial Onset Seizures
Epilepsy
Eligibility:
All Genders
12+ years
Brief Summary
The purpose of this study is to assess the safety of perampanel in the treatment of partial onset seizures in participants of age 12 years and older with epilepsy.
Eligibility Criteria
Inclusion
- Participants prescribed perampanel for the adjunctive treatment of partial onset seizures based on independent clinical judgment of treating physicians.
Exclusion
- Participation in another study involving administration of an investigational drug or device whilst participating in this observational study.
- Hypersensitivity \[allergic\] to perampanel.
Key Trial Info
Start Date :
February 18 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2020
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03836924
Start Date
February 18 2019
End Date
March 1 2020
Last Update
February 18 2021
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
BGS Gleneagles Global Hospitals
Bengaluru, Karnataka, India, 560060
2
Seth G S Medical College & KEM Hospital
Mumbai, Maharashtra, India, 400012
3
Brain Clinic, Jasleen Hospital
Nagpur, Maharashtra, India, 440012
4
Getwell Hospital and Research Institute
Nagpur, Maharashtra, India, 440012